INITIAL combination therapy with vildagliptin/metformin in drug-naive Asian type 2 diabetes patients: influence of age, BMI and co-morbidities in a real world setting

被引：0
|
作者：
Mirasol, R. C. [1 ]
Pathan, M. F. [2 ]
Chawla, M. [3 ]
Kim, T. H. [4 ]
Cooke, K. [5 ]
Hours-Zesiger, P. [5 ]
Shete, A. [5 ]
机构：
[1] St Lukes Med Ctr, Quezon City, Philippines
[2] BIRDEM Hosp, Dhaka, Bangladesh
[3] LINA Diabet Care Ctr, Mumbai, Maharashtra, India
[4] Seoul Med Ctr, Seoul, South Korea
[5] Novartis Pharma AG, Basel, Switzerland
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
774
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [41] Sustained efficacy and tolerability of vildagliptin monotherapy during one-year treatment of drug-naive patients with type 2 diabetes
    Goekel, B.
    Schweizer, A.
    Couturier, A.
    LeBeaut, A.
    Dejager, S.
    DIABETOLOGIA, 2006, 49 : 28 - 28
  • [42] Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial
    Pan, Chang Yu
    Yang, Wenying
    Tou, Conrad
    Gause-Nilsson, Ingrid
    Zhao, June
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 (03) : 268 - 275
  • [43] Comparative efficacy of saxagliptin combination therapy with acarbose, or gliclazide modified release, or metformin in drug naive patients with type 2 diabetes
    Chen, X. P.
    Li, H. M.
    Kuang, H. Y.
    Chen, L.
    Ma, J. H.
    Zhang, Q.
    Pan, T. R.
    He, J.
    Yang, W. Y.
    DIABETOLOGIA, 2018, 61 : S377 - S377
  • [44] Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey
    Hiroki Murayama
    Kota Imai
    Masato Odawara
    Diabetes Therapy, 2018, 9 : 1185 - 1199
  • [45] Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey
    Murayama, Hiroki
    Imai, Kota
    Odawara, Masato
    DIABETES THERAPY, 2018, 9 (03) : 1185 - 1199
  • [46] Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
    Luc Van Gaal
    Michel P. Hermans
    Evis Daci
    Kris Denhaerynck
    Lut De Meester
    Karen MacDonald
    Ivo Abraham
    Stefaan Vancayzeele
    Michael Maris
    Diabetes Therapy, 2019, 10 : 965 - 979
  • [47] Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study
    Van Gaal, Luc
    Hermans, Michel P.
    Daci, Evis
    Denhaerynck, Kris
    De Meester, Lut
    MacDonald, Karen
    Abraham, Ivo
    Vancayzeele, Stefaan
    Maris, Michael
    DIABETES THERAPY, 2019, 10 (03) : 965 - 979
  • [48] Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    Williams-Herman, D.
    Xu, L.
    Teng, R.
    Golm, G. T.
    Johnson, J.
    Davies, M. J.
    Kaufman, K. D.
    Goldstein, B. J.
    DIABETES OBESITY & METABOLISM, 2012, 14 (01): : 67 - 76
  • [49] Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus
    Rosenstock, J.
    Niggli, M.
    Maldonado-Lutomirsky, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (06): : 571 - 578
  • [50] Rosiglitazone and metformin fixed-dose combination provides superior glycaemic control compared to metformin and rosiglitazone monotherapies, and was well tolerated in drug-naive type 2 diabetes patients
    Chou, H
    Rood, J
    Biswas, N
    Strow, L
    Krebs, J
    Parikh, S
    Huang, C
    Cobitz, AR
    DIABETOLOGIA, 2005, 48 : A278 - A279
12345